Understanding why clinical trials fail recruitment is critical for life sciences teams. Between 80% and 86% of clinical trials fail to meet enrollment timelines. Around 11% of sites enroll zero participants. Patient recruitment and retention account for 30% to 40% of total trial costs.
I am exploring how AI powered clinical trial services can structurally fix this problem across three areas:
Problem 1: AI Patient Identification Clinical Trials
Traditional recruitment relies on manual chart reviews and physician referrals. This misses the majority of eligible patients. How are teams implementing real-time EHR scanning to surface eligible participants programmatically against protocol eligibility criteria?
Current approaches being evaluated:
- FHIR-based patient matching pipelines
- NLP models parsing unstructured clinical notes
- Genomic data lake queries for biomarker-matched cohort identification
Problem 2: Clinical Trial Recruitment Solutions Using Real-World Data
Approximately 70% of sites fail to meet projected enrollment targets. What data sources and models are teams using for AI-driven site selection?
Current approaches being evaluated:
- Epidemiological and claims data layered with geographic patient density models
- LIMS and EHR integration for site-level eligibility scoring
- Genomic and multi-omics data to match sites to biomarker-specific protocols
Problem 3: Decentralized Clinical Trial Platform Infrastructure
Logistical burden on participants is a leading cause of dropout. What cloud and API architectures are teams using to support decentralized or hybrid trial models?
Current approaches being evaluated:
- Remote monitoring pipelines with HIPAA-compliant data collection
- Cloud bioinformatics infrastructure for distributed data processing
- Digital biomarker capture integrated into trial data management systems
What I am looking for
Practical implementation guidance, architecture patterns, or tool recommendations across any of these three areas. References to open-source frameworks, production case studies, or platform comparisons are welcome.
Top comments (0)